🔒4/23 Private Investor Dinner: By Approval Only
This event is for accredited investors, family offices, fund managers, high net worth individuals, and select angels who are actively investing in public growth-stage companies.
Key Highlights of the Presenting Company
Advancing a non invasive diagnostic screening strategy centered on proprietary biosensor technologies designed to deliver rapid, real time detection across workplace safety, healthcare, and regulated testing environments.
Focused on commercializing fingerprint based drug screening systems and adjacent biosensing applications, the platform is built around portable point of care solutions that eliminate the need for blood, saliva, or urine collection while improving hygiene, speed, and user compliance.
The strategy emphasizes scaling device deployment alongside recurring consumable revenue streams, creating an integrated hardware and cartridge model designed to support margin expansion as installed system volume grows.
Core development efforts are directed toward expanding substance detection panels, enhancing analytical sensitivity, and advancing regulatory clearances to broaden addressable market access across the United States and international jurisdictions.
Parallel initiatives include manufacturing optimization and supply chain partnerships aimed at lowering unit production costs, improving gross margins, and supporting anticipated demand growth tied to regulatory and enterprise adoption.
With drug screening and impairment detection remaining critical across transportation, construction, energy, and public safety sectors, the company is positioning its technology as a next generation alternative to legacy testing modalities constrained by invasiveness, processing delays, and logistical complexity.
Ongoing technical and clinical validation programs are supporting regulatory submissions, product iteration, and data generation required for expanded commercialization pathways and institutional procurement adoption.
Backed by leadership experience spanning diagnostics development, medical device commercialization, and global distribution scaling, the platform offers exposure to emerging non invasive screening technologies aligned with evolving workplace compliance and safety mandates.
At the lunch, management will outline commercialization progress, discuss regulatory advancement milestones, and frame how the company is positioning its diagnostic platform within the rapidly modernizing drug screening and biosensor technology landscape.
How it works:
Apply to attend
Approval required: applicants will be vetted and notified if accepted
Location details will be confirmed upon acceptance
✅ Business cards will be collected
👔 Business attire required
🚫 No +1s allowed; invitations are non-transferable
📅 Agenda:
5:30 – 6:00 PM | Cocktail Reception
6:00 – 6:45 PM | Company Presentation & Dinner
6:45 – 7:15 PM | Q&A Session
7:15 PM | Meeting concludes; optional private discussions until 8:00 PM